Mumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received ...

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established ...

The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Tablets for heart failure patients.

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...

( MENAFN - Swissinfo) Swiss Pharmaceutical heavyweight Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug. Core operating profit ...

NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides ...

Novartis said Friday that it expects core operating profit--one of its preferred metrics, which strips out exceptional items--for 2025 to grow in the high-single-digit to low-double-digit range and ...

In the corporate sector, Novartis (SIX: NOVN) stock rose 4% after Swiss drugmaker reported strong fourth-quarter results ...